EP3017815A4 - Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm - Google Patents

Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm Download PDF

Info

Publication number: EP3017815A4
Authority: EP; European Patent Office
Prior art keywords: naringenin; preventing; aortic aneurysm; abdominal aortic; preparing drugs
Prior art date: 2013-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14818368.4A

Other languages

German (de)

French (fr)

Other versions

EP3017815A1 (en

EP3017815B1 (en

Inventor

Wei Kong

Qinghua CUI

Ziyi Liu

Fang Yu

Jingang ZHENG

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Peking University

Original Assignee

Peking University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-27

Filing date

2014-01-24

Publication date

2017-01-25

2014-01-24 Application filed by Peking University filed Critical Peking University

2016-05-11 Publication of EP3017815A1 publication Critical patent/EP3017815A1/en

2017-01-25 Publication of EP3017815A4 publication Critical patent/EP3017815A4/en

2020-12-09 Application granted granted Critical

2020-12-09 Publication of EP3017815B1 publication Critical patent/EP3017815B1/en

Status Active legal-status Critical Current

2034-01-24 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nutrition Science (AREA)
Botany (AREA)
Mycology (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP14818368.4A 2013-06-27 2014-01-24 Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm Active EP3017815B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201310264289.3A CN103340849B (en)	2013-06-27	2013-06-27	Application of naringenin in preparing medicament for preventing and/or treating abdominal aortic aneurysm
PCT/CN2014/000093 WO2014206056A1 (en)	2013-06-27	2014-01-24	Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm

Publications (3)

Publication Number	Publication Date
EP3017815A1 EP3017815A1 (en)	2016-05-11
EP3017815A4 true EP3017815A4 (en)	2017-01-25
EP3017815B1 EP3017815B1 (en)	2020-12-09

Family

ID=49275712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14818368.4A Active EP3017815B1 (en)	2013-06-27	2014-01-24	Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm

Country Status (4)

Country	Link
US (1)	US9669005B2 (en)
EP (1)	EP3017815B1 (en)
CN (1)	CN103340849B (en)
WO (1)	WO2014206056A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103340849B (en) *	2013-06-27	2015-01-28	北京大学	Application of naringenin in preparing medicament for preventing and/or treating abdominal aortic aneurysm
CN105078957B (en) *	2014-05-04	2017-11-21	中国医学科学院基础医学研究所	Trihydroxyflavone is preparing the purposes in being used to treat or prevent the medicine of abdominal aneurvsm
CN105596324A (en) *	2015-12-21	2016-05-25	郑金刚	Application of naringenin to preparation of drugs for preventing and/or treating aortic dissection
KR101751486B1 (en) *	2016-03-02	2017-06-28	광주과학기술원	Composition for Enhancing BKCa Channel
CN109771412A (en) *	2018-12-29	2019-05-21	遵义医学院	Drugs and Rat Model Construction Methods for Relieving Vascular Restenosis After Balloon Injury
CN109806384A (en) *	2019-02-28	2019-05-28	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	A mouse model of abdominal aortic aneurysm by intraperitoneal injection of benzopyrene combined with angiotensin Ⅱ
CN111184709B (en) *	2020-01-20	2021-03-23	北京大学	Application of HPMC and naringenin isonicotinamide co-crystal in preparation of medicine for preventing and treating abdominal aortic aneurysm
CN116870046B (en) *	2020-06-02	2024-09-20	中国科学院上海药物研究所	Use of natural compounds and derivatives thereof for the treatment of arterial lesions
CN112972655A (en) *	2021-04-16	2021-06-18	武汉大学	Application of interleukin 12 in preparation of medicine for preventing, relieving and/or treating aortic aneurysm
CN116530469B (en) *	2023-07-06	2023-09-19	首都医科大学	Preparation methods and applications of animal models of abdominal aortic aneurysm

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100278914A1 (en) *	2007-08-23	2010-11-04	Min-Young Kim	Fraction of melissa leaf extract having angiogenesis and mmp inhibitory activities, and composition comprising the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102438614A (en) *	2008-10-10	2012-05-02	利默里克生物制药公司	Pyrone analogs for therapeutic treatment
CN102451168B (en) *	2010-10-29	2013-07-31	河南天方药业股份有限公司	Preparation method of naringenin tablet
CN102302483A (en) *	2011-07-08	2012-01-04	中国科学院生物物理研究所	Application of flavonoid small molecule medicine in anti-inflammation and associated diseases
CN103340849B (en) *	2013-06-27	2015-01-28	北京大学	Application of naringenin in preparing medicament for preventing and/or treating abdominal aortic aneurysm

2013
- 2013-06-27 CN CN201310264289.3A patent/CN103340849B/en active Active
2014
- 2014-01-24 WO PCT/CN2014/000093 patent/WO2014206056A1/en not_active Ceased
- 2014-01-24 US US14/901,692 patent/US9669005B2/en active Active
- 2014-01-24 EP EP14818368.4A patent/EP3017815B1/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100278914A1 (en) *	2007-08-23	2010-11-04	Min-Young Kim	Fraction of melissa leaf extract having angiogenesis and mmp inhibitory activities, and composition comprising the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DASTMALCHI ET AL: "Chemical composition and in vitro antioxidative activity of a lemon balm (Melissa officinalis L.) extract", LWT- FOOD SCIENCE AND TECHNOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 41, no. 3, 27 November 2007 (2007-11-27), pages 391 - 400, XP022365063, ISSN: 0023-6438, DOI: 10.1016/J.LWT.2007.03.007 *
M.J. DAVIES: "Aortic Aneurysm Formation : Lessons From Human Studies and Experimental Models", CIRCULATION, vol. 98, no. 3, 21 July 1998 (1998-07-21), US, pages 193 - 195, XP055330645, ISSN: 0009-7322, DOI: 10.1161/01.CIR.98.3.193 *
R. LIM ET AL: "Dietary phytophenols curcumin, naringenin and apigenin reduce infection-induced inflammatory and contractile pathways in human placenta, foetal membranes and myometrium", MOLECULAR HUMAN REPRODUCTION., vol. 19, no. 7, 26 March 2013 (2013-03-26), GB - BE, pages 451 - 462, XP055330684, ISSN: 1360-9947, DOI: 10.1093/molehr/gat015 *
See also references of WO2014206056A1 *

Also Published As

Publication number	Publication date
EP3017815A1 (en)	2016-05-11
CN103340849B (en)	2015-01-28
WO2014206056A1 (en)	2014-12-31
CN103340849A (en)	2013-10-09
US20160367523A1 (en)	2016-12-22
EP3017815B1 (en)	2020-12-09
US9669005B2 (en)	2017-06-06

Publication	Publication Date	Title
EP3017815A4 (en)	2017-01-25	Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm
IL242610A0 (en)	2016-02-01	Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP3072517A4 (en)	2017-05-17	Use of ginsenoside-rg3 in preparing medicine for preventing or/and treating dementia and medicine
IL247211A0 (en)	2016-09-29	Systems and methods for tissue healing
EP3013407A4 (en)	2017-05-31	Medical treatment system and method of use
IL249189A0 (en)	2017-01-31	Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
EP2967995A4 (en)	2017-04-26	Corneal implant systems and methods
HUE039560T2 (en)	2019-01-28	Microclosures and related methods for skin treatment
EP2890440A4 (en)	2016-06-08	Devices and methods for the treatment of vascular disease
DK2994173T3 (en)	2021-10-11	Wound healing and tissue engineering
EP2858719A4 (en)	2017-04-19	Systems and methods for tissue treatment
EP3038584A4 (en)	2017-05-03	System and method for off-loading of the body in the prone position and for patient turning and repositioning
EP2967523A4 (en)	2017-03-15	Tissue and vascular closure devices and methods of use thereof
EP3061452A4 (en)	2017-05-03	Use of icaritin in preparing medicament for preventing or treating hematocytopenia
EP2991710A4 (en)	2017-01-04	Systems and methods for anchoring medical devices
PL3004108T3 (en)	2018-03-30	Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
PL3004112T3 (en)	2018-02-28	Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EP2958492A4 (en)	2016-08-17	Tissue expanders, implants, and methods of use
EP2956201A4 (en)	2017-01-18	Systems and methods for anchoring medical devices
SMT201900573T1 (en)	2019-11-13	Pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof
PL2857536T4 (en)	2016-08-31	Implant for patients in growth, method for its preparation and use
EP3016607A4 (en)	2017-03-29	Systems and methods for in vivo irradiation of blood
IL246286A0 (en)	2016-07-31	Pharmaceutical preparation for preventing and treating progressive myopia
EP2999417A4 (en)	2017-04-26	Surgical implant system and method
ZA201804198B (en)	2019-04-24	Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body

Legal Events

Date	Code	Title	Description
2016-04-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-05-11	17P	Request for examination filed	Effective date: 20160115
2016-05-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-05-11	AX	Request for extension of the european patent	Extension state: BA ME
2016-10-05	DAX	Request for extension of the european patent (deleted)
2017-01-25	A4	Supplementary search report drawn up and despatched	Effective date: 20170104
2017-01-25	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/352 20060101AFI20161222BHEP Ipc: A23L 33/00 20160101ALI20161222BHEP Ipc: A61P 35/00 20060101ALI20161222BHEP Ipc: A61P 9/00 20060101ALI20161222BHEP Ipc: A61P 29/00 20060101ALI20161222BHEP Ipc: A23L 33/105 20160101ALI20161222BHEP
2019-09-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-10-09	17Q	First examination report despatched	Effective date: 20190910
2020-08-06	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2020-08-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2020-09-02	INTG	Intention to grant announced	Effective date: 20200807
2020-10-31	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2020-11-06	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2020-11-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2020-12-09	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-12-09	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2020-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1342667 Country of ref document: AT Kind code of ref document: T Effective date: 20201215 Ref country code: CH Ref legal event code: EP
2020-12-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014073237 Country of ref document: DE
2021-01-06	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2021-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210309 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2021-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1342667 Country of ref document: AT Kind code of ref document: T Effective date: 20201209
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210309
2021-06-17	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20201209
2021-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2021-07-12	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210409 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2021-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2021-08-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2021-09-10	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602014073237 Country of ref document: DE
2021-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210409 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210124
2021-10-06	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20210131
2021-10-15	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2021-10-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2021-10-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2021-11-17	26N	No opposition filed	Effective date: 20210910
2021-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210124
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210409
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131
2023-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140124
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209
2025-04-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20250120 Year of fee payment: 12
2025-04-25	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250120 Year of fee payment: 12
2025-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250120 Year of fee payment: 12